Drug maker InterMune Inc. has agreed to pay the government $37 million to settle charges it promoted a drug to treat a fatal lung disease even though it was approved for a different ailment and its own studies didn't show it was effective. The drug Actimmune is approved by the FDA to treat an immune system disorder and a bone disease but was often prescribed off-label to treat a lung-scarring condition known as idiopathic pulmonary fibrosis, a disease for which there is no FDA-approved treatment.
October 30, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Drug maker InterMune Inc. has agreed to pay $37 million to settle charges it promoted a drug to treat a fatal lung disease even though it was approved for a different ailment and its own studies didn’t show it was effective.
The drug Actimmune is approved by the Food and Drug Administration to treat an immune system disorder and a bone disease but was often prescribed off-label to treat a lung-scarring condition known as idiopathic pulmonary fibrosis.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
